IPOs, Biotech, Archemix

Archemix Sets IPO Terms

Rebecca Zacks 10/23/07

In a new filing with the SEC, Cambridge, MA’s Archemix set terms for its IPO of 4.5 million shares at $12 to $14 per share. The firm, which plans to trade on the NASDAQ Global Market under the symbol “ARCH,” is developing “aptamers,” or short strands of DNA or RNA, as treatments for a variety of ailments.